Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
about
Optimal duration of chemotherapy for advanced non-small cell lung cancerOptimal duration of chemotherapy for advanced non-small cell lung cancerOptimizing the management of advanced non-small-cell lung cancer: a personal viewMetastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapiesComparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis.A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancersA phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.Radiation therapy with concurrent chemotherapy for locally advanced cervical carcinoma: outcome analysis with emphasis on the impact of treatment duration on outcomeWhat is the role of maintenance therapy in the treatment of non-small cell lung cancer?Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials.Pharmacogenomics: a reality or still a promise?Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer.Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future.Emerging ethnic differences in lung cancer therapy.Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinomaRandomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer.Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation.Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.Metabolism of the taxanes including nab-paclitaxel.Treatment regimens of classical and newer taxanes.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancerA randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.Management of elderly patients with advanced non-small cell lung cancer: a single-center experience.Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.Lung cancer: New biological insights and recent therapeutic advances.Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer.Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer.
P2860
Q24200970-5F8987FC-DEB4-4011-ADE5-EBDAA143AC12Q24242409-0F6F657D-642C-4049-B1F4-30197868C08CQ24656144-B5534953-0CA2-41B7-BF2F-1D678D466E9EQ28083840-FCA7771F-175E-4F10-A490-4751B20786B4Q33412557-E681220D-2500-4827-9C43-4B06B22E8073Q33422985-7C7C4B08-7D9A-4E94-A906-573F347161F4Q34247227-9DE0A4E9-5F26-48D5-9E7A-B14C04AC21A4Q34300117-4334EBE9-2A26-4A46-B7AB-B25F3BE5E8EEQ34450520-6B219924-D825-46AD-9004-D60A633D3793Q34546780-C43E88E1-3F1F-4FD1-9FEE-9386957F57BFQ35076269-2E2E661A-450F-4513-8018-E877F8E51D67Q35111780-F20B65CA-57E4-4EA8-BE40-A1BA99C77C0AQ35565186-74225B55-9D69-4A8F-9E3F-649EB0629E8BQ35811836-84012679-698A-4B27-B1CE-9C8107D0AF0DQ35858069-B0196D32-D62D-41E3-9495-54F07005CC5EQ36448679-31974013-556F-495C-97FE-6951469D1E57Q36521844-E043C5EC-E45D-4A4E-B7EC-F1CB46358F0BQ37010547-1B99C8DF-D546-4C7E-A180-63B84766B6F7Q37321033-69BE75B0-9D47-4583-92BF-4D8EC26FCEDAQ37449257-4D167FE6-8E91-4085-9362-A830F0F50A36Q37992189-AC44ADF8-4A98-4259-A201-710E91AA92FCQ38258744-37EA327F-1FA8-4EC1-B137-3C03353864ABQ38267987-2F94E838-842F-486C-AAF0-AC4B98A1DC98Q38641136-C2534C76-AD8B-475F-AC6C-D71D303E697BQ38742506-5735C8AE-9F76-47D5-B12F-9240E269DD63Q38847914-2A19179D-9182-4768-ADF4-B779A6B2DF5DQ38948699-A5E5934B-6F05-4A95-850F-7230DA2EF286Q39981409-21D9B0CC-FA4E-4B7A-8E5D-89ED6D04015FQ40294108-7025C4CF-B5F5-416E-B5B4-7A56BF0B4B8DQ40315977-5F3020F6-47A3-463E-967C-D89F14C3875AQ40342327-FE34E5C8-280F-41B4-9D5A-52CEE94E6036Q43260541-38CAA459-2D53-4703-BC74-2A932D4DA06AQ44244242-7690D18B-A959-4421-AD0D-0D40D722A706Q45126932-F2446EAD-64BC-4414-81F7-D9DC2450EC1DQ46049056-6D488B72-3C9E-4E7D-BFB2-617B2A8A2756Q47376469-9FCA4884-040C-4AB5-9B6B-ECDE649FBC1FQ47828906-A043BA77-59EC-40B4-B838-A68708EAA3C3Q55284746-26DBE229-1988-4869-BD3E-67055A1A9BA9
P2860
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Randomized phase III trial com ...... ic non-small cell lung cancer.
@en
Randomized phase III trial com ...... ic non-small cell lung cancer.
@nl
type
label
Randomized phase III trial com ...... ic non-small cell lung cancer.
@en
Randomized phase III trial com ...... ic non-small cell lung cancer.
@nl
prefLabel
Randomized phase III trial com ...... ic non-small cell lung cancer.
@en
Randomized phase III trial com ...... ic non-small cell lung cancer.
@nl
P2093
P356
P1433
P1476
Randomized phase III trial com ...... ic non-small cell lung cancer.
@en
P2093
D Waterhouse
M A Socinski
R B Natale
R Lilenbaum
P304
P356
10.1093/ANNONC/MDI216
P577
2005-04-28T00:00:00Z